{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:43:32Z","timestamp":1793119412601,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the doctor initiation fund of the affiliated hospital of southwest medical university","award":["19064"],"award-info":[{"award-number":["19064"]}]},{"name":"he key project of natural science of southwest medical university","award":["2020ZRZD004"],"award-info":[{"award-number":["2020ZRZD004"]}]},{"name":"the sichuan science and technology program","award":["2019YFS0537 and 2020YFS0456"],"award-info":[{"award-number":["2019YFS0537 and 2020YFS0456"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Maresin-1 (MaR1) is an anti-inflammatory pro-resolving mediator and is considered a potential regulator of metabolic diseases. Non-alcoholic fatty liver disease (NAFLD) is a very common metabolic liver disease. However, little information is available on the relationship between MaR1 and NAFLD in humans. Therefore, the study explored the association between serum MaR1 levels and NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional study was conducted in 240 Chinese people, including 116 non-NAFLD subjects and 124 NAFLD patients. Serum MaR1 levels were determined by enzyme-linked immunosorbent assay (ELISA). The association between MaR1 and NAFLD was assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Circulating MaR1 levels in NAFLD patients were markedly lower than those in non-NAFLD subjects (63.63 [59.87\u201373.93] vs 73.11 [65.12\u201384.50] pg\/mL, <jats:italic>P<\/jats:italic>\u2009=\u20090.000). The percentages of patients with NAFLD gradually decreased with the increase of MaR1 quartiles (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Furthermore, serum MaR1 levels were positively associated with aspartate aminotransferase\/alanine aminotransferase (AST\/ALT), albumin, the albumin-globulin-ratio, and high-density lipoprotein cholesterol (HDL-C) (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) and negatively associated with body mass index (BMI), waist circumference, hip circumference, the waist-to-hip ratio, ALT, gamma-glutamyl transpeptidase (GGT), uric acid, triglyceride (TG), and fasting blood glucose (FBG) (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) after adjusting for sex and age. Binary logistic regression analysis revealed that serum MaR1 levels were significantly associated with NAFLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Circulating MaR1 levels were decreased in patients with NAFLD, and a negative correlation was identified between NAFLD and serum MaR1 concentrations. Decreased MaR1 might be involved in the development of NAFLD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01518-5","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T12:02:54Z","timestamp":1630324974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study"],"prefix":"10.1186","volume":"20","author":[{"given":"Xia","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahao","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-6252","authenticated-orcid":false,"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"issue":"2","key":"1518_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrgastro.2016.160","volume":"14","author":"SR Wesolowski","year":"2017","unstructured":"Wesolowski SR, Kasmi KC, Jonscher KR, Friedman JE. Developmental origins of NAFLD: a womb with a clue. Nat Rev Gastroenterol Hepatol. 2017;14(2):81\u201396. https:\/\/doi.org\/10.1038\/nrgastro.2016.160.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"1518_CR2","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672\u201382. https:\/\/doi.org\/10.1002\/hep.30251.","journal-title":"Hepatology."},{"issue":"47","key":"1518_CR3","doi-asserted-by":"publisher","first-page":"17932","DOI":"10.3748\/wjg.v20.i47.17932","volume":"20","author":"RN Feng","year":"2014","unstructured":"Feng RN, Du SS, Wang C, Li YC, Liu LY, Guo FC, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20(47):17932\u201340. https:\/\/doi.org\/10.3748\/wjg.v20.i47.17932.","journal-title":"World J Gastroenterol"},{"issue":"18","key":"1518_CR4","doi-asserted-by":"publisher","first-page":"5695","DOI":"10.3748\/wjg.v21.i18.5695","volume":"21","author":"JZ Zhu","year":"2015","unstructured":"Zhu JZ, Zhou QY, Wang YM, Dai YN, Zhu J, Yu CH, et al. Prevalence of fatty liver disease and the economy in China: a systematic review. World J Gastroenterol. 2015;21(18):5695\u2013706. https:\/\/doi.org\/10.3748\/wjg.v21.i18.5695.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1518_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"1","key":"1518_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00535-014-0948-9","volume":"50","author":"K Nishioji","year":"2015","unstructured":"Nishioji K, Sumida Y, Kamaguchi M, Mochizuki N, Kobayashi M, Nishimura T, et al. Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012. J Gastroenterol. 2015;50(1):95\u2013108. https:\/\/doi.org\/10.1007\/s00535-014-0948-9.","journal-title":"J Gastroenterol"},{"issue":"5","key":"1518_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64(5):1577\u201386. https:\/\/doi.org\/10.1002\/hep.28785.","journal-title":"Hepatology."},{"issue":"5","key":"1518_CR8","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","volume":"152","author":"D Goldberg","year":"2017","unstructured":"Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017;152(5):1090\u20139. https:\/\/doi.org\/10.1053\/j.gastro.2017.01.003.","journal-title":"Gastroenterology."},{"issue":"3","key":"1518_CR9","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547\u201355. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.039.","journal-title":"Gastroenterology."},{"issue":"1","key":"1518_CR10","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2015.07.019","volume":"14","author":"S Mittal","year":"2016","unstructured":"Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124\u201331. https:\/\/doi.org\/10.1016\/j.cgh.2015.07.019.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"1518_CR11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.nut.2012.03.006","volume":"29","author":"UN Das","year":"2013","unstructured":"Das UN. Nonalcoholic fatty liver disease as a pro-resolution defective disorder. Nutrition. 2013;29(1):345\u20139. https:\/\/doi.org\/10.1016\/j.nut.2012.03.006.","journal-title":"Nutrition."},{"issue":"11","key":"1518_CR12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.4239\/wjd.v2.i11.176","volume":"2","author":"UN Das","year":"2011","unstructured":"Das UN. A defect in the activities of Delta and Delta desaturases and pro-resolution bioactive lipids in the pathobiology of non-alcoholic fatty liver disease. World J Diabetes. 2011;2(11):176\u201388. https:\/\/doi.org\/10.4239\/wjd.v2.i11.176.","journal-title":"World J Diabetes"},{"issue":"4","key":"1518_CR13","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1096\/fj.11-201442","volume":"26","author":"CN Serhan","year":"2012","unstructured":"Serhan CN, Dalli J, Karamnov S, Choi A, Park CK, Xu ZZ, et al. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB J. 2012;26(4):1755\u201365. https:\/\/doi.org\/10.1096\/fj.11-201442.","journal-title":"FASEB J"},{"issue":"1","key":"1518_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1084\/jem.20081880","volume":"206","author":"CN Serhan","year":"2009","unstructured":"Serhan CN, Yang R, Martinod K, Kasuga K, Pillai PS, Porter TF, et al. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med. 2009;206(1):15\u201323. https:\/\/doi.org\/10.1084\/jem.20081880.","journal-title":"J Exp Med"},{"issue":"5","key":"1518_CR15","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1096\/fj.201600859R","volume":"31","author":"L Martinez-Fernandez","year":"2017","unstructured":"Martinez-Fernandez L, Gonzalez-Muniesa P, Laiglesia LM, Sainz N, Prieto-Hontoria PL, Escote X, et al. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in Ob\/Ob and diet-induced obese mice. FASEB J. 2017;31(5):2135\u201345. https:\/\/doi.org\/10.1096\/fj.201600859R.","journal-title":"FASEB J"},{"issue":"3","key":"1518_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/ijo.2017.226","volume":"42","author":"LM Laiglesia","year":"2018","unstructured":"Laiglesia LM, Lorente-Cebrian S, Martinez-Fernandez L, Sainz N, Prieto-Hontoria PL, Burrell MA, et al. Maresin 1 mitigates liver steatosis in Ob\/Ob and diet-induced obese mice. Int J Obes. 2018;42(3):572\u20139. https:\/\/doi.org\/10.1038\/ijo.2017.226.","journal-title":"Int J Obes"},{"issue":"11","key":"1518_CR17","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1074\/jbc.RA117.000885","volume":"293","author":"TW Jung","year":"2018","unstructured":"Jung TW, Kim HC, Abd El-Aty AM, Jeong JH. Maresin 1 attenuates NAFLD by suppression of endoplasmic reticulum stress via AMPK-SERCA2b pathway. J Biol Chem. 2018;293(11):3981\u20138. https:\/\/doi.org\/10.1074\/jbc.RA117.000885.","journal-title":"J Biol Chem"},{"issue":"4","key":"1518_CR18","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1172\/JCI124219","volume":"129","author":"YH Han","year":"2019","unstructured":"Han YH, Shin KO, Kim JY, Khadka DB, Kim HJ, Lee YM, et al. A maresin 1\/RORalpha\/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis. J Clin Invest. 2019;129(4):1684\u201398. https:\/\/doi.org\/10.1172\/JCI124219.","journal-title":"J Clin Invest"},{"issue":"1","key":"1518_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/j.1751-2980.2010.00476.x","volume":"12","author":"JG Fan","year":"2011","unstructured":"Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, et al. Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010: (published in Chinese on Chinese journal of hepatology 2010; 18:163-166). J Dig Dis. 2011;12(1):38\u201344. https:\/\/doi.org\/10.1111\/j.1751-2980.2010.00476.x.","journal-title":"J Dig Dis"},{"issue":"2","key":"1518_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diabet.2019.04.009","volume":"46","author":"X Wang","year":"2020","unstructured":"Wang X, Chen X, Zhang H, Pang J, Lin J, Xu X, et al. Circulating retinol-binding protein 4 is associated with the development and regression of non-alcoholic fatty liver disease. Diabetes Metab. 2020;46(2):119\u201328. https:\/\/doi.org\/10.1016\/j.diabet.2019.04.009.","journal-title":"Diabetes Metab"},{"issue":"5","key":"1518_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","volume":"23","author":"KG Alberti","year":"2006","unstructured":"Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23(5):469\u201380. https:\/\/doi.org\/10.1111\/j.1464-5491.2006.01858.x.","journal-title":"Diabet Med"},{"issue":"10","key":"1518_CR22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.ebiom.2015.09.004","volume":"2","author":"Y Ni","year":"2015","unstructured":"Ni Y, Zhao L, Yu H, Ma X, Bao Y, Rajani C, et al. Circulating unsaturated fatty acids delineate the metabolic status of obese individuals. EBioMedicine. 2015;2(10):1513\u201322. https:\/\/doi.org\/10.1016\/j.ebiom.2015.09.004.","journal-title":"EBioMedicine."},{"key":"1518_CR23","doi-asserted-by":"publisher","first-page":"4539035","DOI":"10.1155\/2020\/4539035","volume":"2020","author":"T Miao","year":"2020","unstructured":"Miao T, Huang B, He N, Sun L, Du G, Gong X, et al. Decreased plasma Maresin 1 concentration is associated with diabetic foot ulcer. Mediat Inflamm. 2020;2020:4539035.","journal-title":"Mediat Inflamm"},{"issue":"3","key":"1518_CR24","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.bbrc.2017.06.170","volume":"490","author":"M Rombaldova","year":"2017","unstructured":"Rombaldova M, Janovska P, Kopecky J, Kuda O. Omega-3 fatty acids promote fatty acid utilization and production of pro-resolving lipid mediators in alternatively activated adipose tissue macrophages. Biochem Biophys Res Commun. 2017;490(3):1080\u20135. https:\/\/doi.org\/10.1016\/j.bbrc.2017.06.170.","journal-title":"Biochem Biophys Res Commun"},{"key":"1518_CR25","doi-asserted-by":"publisher","first-page":"2380319","DOI":"10.1155\/2018\/2380319","volume":"2018","author":"S Tang","year":"2018","unstructured":"Tang S, Wan M, Huang W, Stanton RC, Xu Y. Maresins: specialized Proresolving lipid mediators and their potential role in inflammatory-related diseases. Mediat Inflamm. 2018;2018:2380319.","journal-title":"Mediat Inflamm"},{"issue":"2","key":"1518_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/asia.201000494","volume":"6","author":"K Sasaki","year":"2011","unstructured":"Sasaki K, Urabe D, Arai H, Arita M, Inoue M. Total synthesis and bioactivities of two proposed structures of maresin. Chem Asian J. 2011;6(2):534\u201343. https:\/\/doi.org\/10.1002\/asia.201000494.","journal-title":"Chem Asian J"},{"issue":"48","key":"1518_CR27","doi-asserted-by":"publisher","first-page":"40161","DOI":"10.1074\/jbc.M112.417014","volume":"287","author":"AC Tosello-Trampont","year":"2012","unstructured":"Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem. 2012;287(48):40161\u201372. https:\/\/doi.org\/10.1074\/jbc.M112.417014.","journal-title":"J Biol Chem"},{"issue":"11","key":"1518_CR28","doi-asserted-by":"publisher","first-page":"e112327","DOI":"10.1371\/journal.pone.0112327","volume":"9","author":"A Wehr","year":"2014","unstructured":"Wehr A, Baeck C, Ulmer F, Gassler N, Hittatiya K, Luedde T, et al. Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. PLoS One. 2014;9(11):e112327. https:\/\/doi.org\/10.1371\/journal.pone.0112327.","journal-title":"PLoS One"},{"issue":"1","key":"1518_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","volume":"27","author":"VT Samuel","year":"2018","unstructured":"Samuel VT, Shulman GI. Nonalcoholic fatty liver disease as a Nexus of metabolic and hepatic diseases. Cell Metab. 2018;27(1):22\u201341. https:\/\/doi.org\/10.1016\/j.cmet.2017.08.002.","journal-title":"Cell Metab"},{"issue":"4","key":"1518_CR30","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/liv.12454","volume":"34","author":"NH Kim","year":"2014","unstructured":"Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver Int. 2014;34(4):604\u201311. https:\/\/doi.org\/10.1111\/liv.12454.","journal-title":"Liver Int"},{"key":"1518_CR31","doi-asserted-by":"publisher","first-page":"2309175","DOI":"10.1155\/2019\/2309175","volume":"2019","author":"Y Hao","year":"2019","unstructured":"Hao Y, Zheng H, Wang RH, Li H, Yang LL, Bhandari S, et al. Maresin1 alleviates metabolic dysfunction in septic mice: a (1)H NMR-based metabolomics analysis. Mediat Inflamm. 2019;2019:2309175.","journal-title":"Mediat Inflamm"},{"issue":"1","key":"1518_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13105-020-00775-9","volume":"77","author":"L Martinez-Fernandez","year":"2021","unstructured":"Martinez-Fernandez L, Gonzalez-Muniesa P, Sainz N, Escote X, Martinez JA, Arbones-Mainar JM, et al. Maresin 1 regulates insulin signaling in human adipocytes as well as in adipose tissue and muscle of lean and obese mice. J Physiol Biochem. 2021;77(1):167\u201373. https:\/\/doi.org\/10.1007\/s13105-020-00775-9.","journal-title":"J Physiol Biochem"},{"issue":"6","key":"1518_CR33","doi-asserted-by":"publisher","first-page":"e21592","DOI":"10.1096\/fj.202002531R","volume":"35","author":"E Felix-Soriano","year":"2021","unstructured":"Felix-Soriano E, Sainz N, Gil-Iturbe E, Collantes M, Fernandez-Galilea M, Castilla-Madrigal R, et al. Changes in brown adipose tissue lipid mediator signatures with aging, obesity, and DHA supplementation in female mice. FASEB J. 2021;35(6):e21592. https:\/\/doi.org\/10.1096\/fj.202002531R.","journal-title":"FASEB J"},{"issue":"6","key":"1518_CR34","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13393","volume":"20","author":"JF Markworth","year":"2021","unstructured":"Markworth JF, Brown LA, Lim E, Castor-Macias JA, Larouche J, Macpherson PCD, et al. Metabolipidomic profiling reveals an age-related deficiency of skeletal muscle pro-resolving mediators that contributes to maladaptive tissue remodeling. Aging Cell. 2021;20(6):e13393. https:\/\/doi.org\/10.1111\/acel.13393.","journal-title":"Aging Cell"},{"issue":"7","key":"1518_CR35","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322. https:\/\/doi.org\/10.1038\/s41591-018-0104-9.","journal-title":"Nat Med"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01518-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01518-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01518-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T12:08:23Z","timestamp":1630325303000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01518-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1518"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01518-5","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"assertion":[{"value":"13 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Human Research Ethics Committee of the Affiliated Hospital of Southwest Medical University approved the experimental protocols (permission no. KY2021086). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}